Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Dawn E. Colburn; Deborah A. Thomas; Francis J. Giles

doi:10.1023/A:1022984830258

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Dawn E. Colburn
, Deborah A. Thomas
, Francis J. Giles

The University of Texas Health Science Center at Houston

Research output: Contribution to a Journal (Peer & Non Peer) › Article › peer-review

6 Citations (Scopus)

Abstract

Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m² given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

Original language	English
Pages (from-to)	109-111
Number of pages	3
Journal	Investigational New Drugs
Volume	21
Issue number	1
DOIs	https://doi.org/10.1023/A:1022984830258
Publication status	Published - Feb 2003
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Acute lymphocytic leukemia
Adult
Paclitaxel
Refractory

Access to Document

10.1023/A:1022984830258

Cite this

@article{c75c1ffe984d4c0ea6ea08edf01a29da,

title = "Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia",

abstract = "Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.",

keywords = "Acute lymphocytic leukemia, Adult, Paclitaxel, Refractory",

author = "Colburn, \{Dawn E.\} and Thomas, \{Deborah A.\} and Giles, \{Francis J.\}",

year = "2003",

month = feb,

doi = "10.1023/A:1022984830258",

language = "English",

volume = "21",

pages = "109--111",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

AU - Colburn, Dawn E.

AU - Thomas, Deborah A.

AU - Giles, Francis J.

PY - 2003/2

Y1 - 2003/2

N2 - Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

AB - Background: A phase II study of paclitaxel in patients with relapsed adult acute lymphocytic leukemia (ALL) was conducted. Methods: Patients with relapsed ALL, no more than one prior salvage regimen, and no overt hepatic, renal, or cardiac dysfunction were eligible. Patients received paclitaxel 250 mg/m2 given as a continuous 24 -h intravenous infusion repeated every 3-4 weeks. Results: Eight patients received 13 courses of paclitaxel. One transient partial response was observed. The only severe extramedullary toxicities observed were Grade 3 myalgias and arthralgias. Conclusion: The study paclitaxel regimen was ineffective in refractory adult ALL.

KW - Acute lymphocytic leukemia

KW - Adult

KW - Paclitaxel

KW - Refractory

UR - https://www.scopus.com/pages/publications/0038353443

U2 - 10.1023/A:1022984830258

DO - 10.1023/A:1022984830258

M3 - Article

SN - 0167-6997

VL - 21

SP - 109

EP - 111

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this